Immunic (NASDAQ:IMUX) Announces Earnings Results

Immunic (NASDAQ:IMUX) issued its earnings results on Thursday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02), Zacks reports.

Immunic Stock Performance

Shares of IMUX stock traded up $0.07 on Friday, hitting $1.02. The company had a trading volume of 3,762,695 shares, compared to its average volume of 5,634,886. The firm has a market cap of $133.07 million, a P/E ratio of -1.46 and a beta of 1.58. The stock’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.76. Immunic has a twelve month low of $0.51 and a twelve month high of $1.35.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd bought a new position in Immunic during the 3rd quarter worth approximately $29,000. Two Sigma Investments LP bought a new stake in shares of Immunic in the 3rd quarter valued at $52,000. Virtu Financial LLC acquired a new stake in shares of Immunic during the third quarter worth $99,000. Jane Street Group LLC raised its stake in Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after buying an additional 152,726 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Immunic in the fourth quarter valued at $120,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Roth Mkm started coverage on shares of Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 price target on the stock. D. Boral Capital cut their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Immunic in a research note on Monday, February 9th. Chardan Capital upgraded Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Immunic has a consensus rating of “Buy” and an average price target of $6.60.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.